PHK
KNSA icon

Point72 Hong Kong’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Point72 Hong Kong’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,839
Closed -$328K – 551
2025
Q2 		$328K Buy
+11,839
New +$301K 0.02% 279
2022
Q4 		– Sell
-350
Closed -$4K – 918
2022
Q3 		$4K Buy
350
+290
+483% +$3.3K ﹤0.01% 1808
2022
Q2 		$1K Buy
60
+45
+300% +$420 ﹤0.01% 1816
2022
Q1 		$0 Sell
15
-1,674
-99% -$17.7K ﹤0.01% 2100
2021
Q4 		$20K Sell
1,689
-124
-7% -$1.52K ﹤0.01% 1541
2021
Q3 		$21K Buy
+1,813
New +$23.6K ﹤0.01% 1695
2020
Q3 		– Sell
-2,680
Closed -$68K – 1363
2020
Q2 		$68K Buy
2,680
+2,563
+2,191% +$53.5K 0.01% 695
2020
Q1 		$2K Sell
117
-180
-61% -$2.82K ﹤0.01% 851
2019
Q4 		$3K Sell
297
-55
-16% -$478 ﹤0.01% 1065
2019
Q3 		$3K Sell
352
-631
-64% -$6.97K ﹤0.01% 844
2019
Q2 		$13K Buy
+983
New +$15.3K ﹤0.01% 836
2018
Q3 		– Sell
-262
Closed -$5K – 1046
2018
Q2 		$5K Buy
+262
New +$4.74K ﹤0.01% 707

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Hong Kong's KNSA Position: Q3 2025 in Review

Point72 Hong Kong sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2025, closing a stake of 11,839 shares — an estimated $328K sold.

Point72 Hong Kong first reported a position in KNSA in Q2 2018 and held it in 12 quarters. The position peaked at $328K in Q2 2025. 204 funds tracked by Wall St. Rank hold KNSA as of Q3 2025.

  • Point72 Hong Kong reported no remaining Kiniksa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Point72 Hong Kong sold 11,839 Kiniksa Pharmaceuticals shares in Q3 2025, an estimated $328K.
  • Point72 Hong Kong first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and held it in 12 quarters.
  • Point72 Hong Kong's Kiniksa Pharmaceuticals position peaked at $328K in Q2 2025.
  • 204 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2025.

Based on Point72 Hong Kong's 13F filing for Q3 2025, filed 14 Nov 2025.